Laboratory Medicine ›› 2022, Vol. 37 ›› Issue (3): 295-299.DOI: 10.3969/j.issn.1673-8640.2022.03.021
Previous Articles Next Articles
Received:
2020-05-23
Revised:
2021-03-26
Online:
2022-03-30
Published:
2022-05-10
CLC Number:
Add to citation manager EndNote|Ris|BibTeX
URL: https://www.shjyyx.com/EN/10.3969/j.issn.1673-8640.2022.03.021
检测项目 | 中值 | CV/% | 高值 | CV/% | 判断标准/% | 结论 |
---|---|---|---|---|---|---|
WBC | ||||||
预稀释模式 | (6.87±0.24)×109/L | 3.43 | (16.1±0.37)×109/L | 2.31 | ≤6.00 | 合格 |
常规模式 | (6.78±0.13)×109/L | 1.97 | (16.18±0.25)×109/L | 1.53 | ≤6.00 | 合格 |
RBC | ||||||
预稀释模式 | (4.41±0.09)×1012/L | 2.03 | (5.34±0.10)×1012/L | 1.84 | ≤2.50 | 合格 |
常规模式 | (4.37±0.05)×1012/L | 1.07 | (5.37±0.05)×1012/L | 0.90 | ≤2.50 | 合格 |
Hb | ||||||
预稀释模式 | (119.32±2.39)g/L | 2.00 | (162.2±3.14)g/L | 1.94 | ≤2.00 | 合格 |
常规模式 | (116.41±1.28)g/L | 1.10 | (159.17±1.13)g/L | 0.71 | ≤2.00 | 合格 |
HCT | ||||||
预稀释模式 | (34.03±0.73)% | 2.15 | (45.33±0.86)% | 1.89 | ≤4.0 | 合格 |
常规模式 | (34.51±0.49)% | 1.41 | (46.21±0.58)% | 1.25 | ≤4.0 | 合格 |
PLT | ||||||
预稀释模式 | (255.8±12.96)×109/L | 5.17 | (554.8±16.01)×109/L | 2.89 | ≤8.0 | 合格 |
常规模式 | (257.84±6.24)×109/L | 2.42 | (573.58±10.43)×109/L | 1.82 | ≤8.0 | 合格 |
MCV | ||||||
预稀释模式 | (77.08±0.54)fL | 0.7 | (87.87±0.58)fL | 0.69 | ≤2.50 | 合格 |
常规模式 | (78.89±0.64)fL | 0.81 | (86.03±0.75)fL | 0.87 | ≤2.50 | 合格 |
检测项目 | 中值 | CV/% | 高值 | CV/% | 判断标准/% | 结论 |
MCH | ||||||
预稀释模式 | (27.03±0.19)pg | 0.71 | (30.38±0.3)pg | 0.97 | ≤2.50 | 合格 |
常规模式 | (26.62±0.25)pg | 0.95 | (29.64±0.24)pg | 0.80 | ≤2.50 | 合格 |
MCHC | ||||||
预稀释模式 | (351.15±3.96)g/L | 1.13 | (357.95±4.58)g/L | 1.28 | ≤3.00 | 合格 |
常规模式 | (336.93±3.63)g/L | 1.08 | (344.40±3.97)g/L | 1.15 | ≤3.00 | 合格 |
NEUT# | ||||||
预稀释模式 | (4.33±0.17)×109/L | 3.84 | (11.04±0.27)×109/L | 2.47 | ≤16.0 | 合格 |
常规模式 | (3.02±0.09)×109/L | 3.00 | (7.73±0.18)×109/L | 2.39 | ≤16.0 | 合格 |
LYMPH# | ||||||
预稀释模式 | (1.77±0.22)×109/L | 11.16 | (3.52±0.45)×109/L | 12.76 | ≤16.0 | 合格 |
常规模式 | (1.99±0.06)×109/L | 3.05 | (4.12±0.18)×109/L | 4.30 | ≤16.0 | 合格 |
MONO# | ||||||
预稀释模式 | (0.6±0.18)×109/L | 30.35 | (1.26±0.43)×109/L | 34.48 | ≤40.0 | 合格 |
常规模式 | (0.88±0.04)×109/L | 4.94 | (2.05±0.16)×109/L | 7.63 | ≤40.0 | 合格 |
EO# | ||||||
预稀释模式 | (0.09±0.06)×109/L | 66.67 | (0.13±0.03)×109/L | 19.52 | ≤40.0 | 不合格 |
常规模式 | (0.69±0.05)×109/L | 7.45 | (1.79±0.14)×109/L | 7.61 | ≤40.0 | 合格 |
BASO# | ||||||
预稀释模式 | (0.06±0.01)×109/L | 16.27 | (0.14±0.01)×109/L | 9.25 | ≤50.0 | 合格 |
常规模式 | (0.20±0.01)×109/L | 3.45 | (0.48±0.02)×109/L | 3.19 | ≤50.0 | 合格 |
检测项目 | 中值 | CV/% | 高值 | CV/% | 判断标准/% | 结论 |
---|---|---|---|---|---|---|
WBC | ||||||
预稀释模式 | (6.87±0.24)×109/L | 3.43 | (16.1±0.37)×109/L | 2.31 | ≤6.00 | 合格 |
常规模式 | (6.78±0.13)×109/L | 1.97 | (16.18±0.25)×109/L | 1.53 | ≤6.00 | 合格 |
RBC | ||||||
预稀释模式 | (4.41±0.09)×1012/L | 2.03 | (5.34±0.10)×1012/L | 1.84 | ≤2.50 | 合格 |
常规模式 | (4.37±0.05)×1012/L | 1.07 | (5.37±0.05)×1012/L | 0.90 | ≤2.50 | 合格 |
Hb | ||||||
预稀释模式 | (119.32±2.39)g/L | 2.00 | (162.2±3.14)g/L | 1.94 | ≤2.00 | 合格 |
常规模式 | (116.41±1.28)g/L | 1.10 | (159.17±1.13)g/L | 0.71 | ≤2.00 | 合格 |
HCT | ||||||
预稀释模式 | (34.03±0.73)% | 2.15 | (45.33±0.86)% | 1.89 | ≤4.0 | 合格 |
常规模式 | (34.51±0.49)% | 1.41 | (46.21±0.58)% | 1.25 | ≤4.0 | 合格 |
PLT | ||||||
预稀释模式 | (255.8±12.96)×109/L | 5.17 | (554.8±16.01)×109/L | 2.89 | ≤8.0 | 合格 |
常规模式 | (257.84±6.24)×109/L | 2.42 | (573.58±10.43)×109/L | 1.82 | ≤8.0 | 合格 |
MCV | ||||||
预稀释模式 | (77.08±0.54)fL | 0.7 | (87.87±0.58)fL | 0.69 | ≤2.50 | 合格 |
常规模式 | (78.89±0.64)fL | 0.81 | (86.03±0.75)fL | 0.87 | ≤2.50 | 合格 |
检测项目 | 中值 | CV/% | 高值 | CV/% | 判断标准/% | 结论 |
MCH | ||||||
预稀释模式 | (27.03±0.19)pg | 0.71 | (30.38±0.3)pg | 0.97 | ≤2.50 | 合格 |
常规模式 | (26.62±0.25)pg | 0.95 | (29.64±0.24)pg | 0.80 | ≤2.50 | 合格 |
MCHC | ||||||
预稀释模式 | (351.15±3.96)g/L | 1.13 | (357.95±4.58)g/L | 1.28 | ≤3.00 | 合格 |
常规模式 | (336.93±3.63)g/L | 1.08 | (344.40±3.97)g/L | 1.15 | ≤3.00 | 合格 |
NEUT# | ||||||
预稀释模式 | (4.33±0.17)×109/L | 3.84 | (11.04±0.27)×109/L | 2.47 | ≤16.0 | 合格 |
常规模式 | (3.02±0.09)×109/L | 3.00 | (7.73±0.18)×109/L | 2.39 | ≤16.0 | 合格 |
LYMPH# | ||||||
预稀释模式 | (1.77±0.22)×109/L | 11.16 | (3.52±0.45)×109/L | 12.76 | ≤16.0 | 合格 |
常规模式 | (1.99±0.06)×109/L | 3.05 | (4.12±0.18)×109/L | 4.30 | ≤16.0 | 合格 |
MONO# | ||||||
预稀释模式 | (0.6±0.18)×109/L | 30.35 | (1.26±0.43)×109/L | 34.48 | ≤40.0 | 合格 |
常规模式 | (0.88±0.04)×109/L | 4.94 | (2.05±0.16)×109/L | 7.63 | ≤40.0 | 合格 |
EO# | ||||||
预稀释模式 | (0.09±0.06)×109/L | 66.67 | (0.13±0.03)×109/L | 19.52 | ≤40.0 | 不合格 |
常规模式 | (0.69±0.05)×109/L | 7.45 | (1.79±0.14)×109/L | 7.61 | ≤40.0 | 合格 |
BASO# | ||||||
预稀释模式 | (0.06±0.01)×109/L | 16.27 | (0.14±0.01)×109/L | 9.25 | ≤50.0 | 合格 |
常规模式 | (0.20±0.01)×109/L | 3.45 | (0.48±0.02)×109/L | 3.19 | ≤50.0 | 合格 |
参数 | 预稀释模式 | 常规模式 | 允许偏差 | 符合率/% | 结论 |
---|---|---|---|---|---|
WBC | 7.09(4.78~11.97)×109/L | 7.13(4.96~12.24)×109/L* | ≤5.0% | 92.5 | 合格 |
RBC | (4.01±1.41)×1012/L | (4.03±1.44)×1012/L | ≤2.0% | 67.5 | 不合格 |
Hb | (121.8±41.8)g/L | (120.33±40.96)g/L* | ≤2.0% | 70.0 | 不合格 |
HCT | (35.99±11.70)% | (36.25±11.65)%* | ≤3.0% | 97.5 | 合格 |
PLT | 219(114~280)×109/L | 216(114~299)×109/L* | ≤7% | 95.0 | 合格 |
MCV | (90.75±9.46)fL | (91.26±9.65)fL* | ≤3.0% | 100.0 | 合格 |
MCH | (30.56±3.16)pg | (30.15±3.20)pg* | ≤3.0% | 85.0 | 合格 |
MCHC | (336.9±14.7)g/L | (330.5±14.5)g/L* | ≤3.0% | 82.5 | 合格 |
NEUT# | 3.47(2.46~6.87)×109/L | 3.54(2.55~7.14)×109/L* | ≤15% | 100.0 | 合格 |
LYMPH# | 1.28(0.99~2.48)×109/L | 1.33(0.96~2.65)×109/L* | ≤15% | 97.5 | 合格 |
MONO# | 0.66(0.36~0.87)×109/L | 0.65(0.36~0.91)×109/L | 0.5×109/L | 97.5 | 合格 |
EO# | 0.11(0.03~0.23)×109/L | 0.10(0.03~0.23)×109/L | 0.2×109/L | 97.5 | 合格 |
BASO# | 0.02(0.01~0.04)×109/L | 0.02(0.01~0.04)×109/L | 0.1×109/L | 97.5 | 合格 |
参数 | 预稀释模式 | 常规模式 | 允许偏差 | 符合率/% | 结论 |
---|---|---|---|---|---|
WBC | 7.09(4.78~11.97)×109/L | 7.13(4.96~12.24)×109/L* | ≤5.0% | 92.5 | 合格 |
RBC | (4.01±1.41)×1012/L | (4.03±1.44)×1012/L | ≤2.0% | 67.5 | 不合格 |
Hb | (121.8±41.8)g/L | (120.33±40.96)g/L* | ≤2.0% | 70.0 | 不合格 |
HCT | (35.99±11.70)% | (36.25±11.65)%* | ≤3.0% | 97.5 | 合格 |
PLT | 219(114~280)×109/L | 216(114~299)×109/L* | ≤7% | 95.0 | 合格 |
MCV | (90.75±9.46)fL | (91.26±9.65)fL* | ≤3.0% | 100.0 | 合格 |
MCH | (30.56±3.16)pg | (30.15±3.20)pg* | ≤3.0% | 85.0 | 合格 |
MCHC | (336.9±14.7)g/L | (330.5±14.5)g/L* | ≤3.0% | 82.5 | 合格 |
NEUT# | 3.47(2.46~6.87)×109/L | 3.54(2.55~7.14)×109/L* | ≤15% | 100.0 | 合格 |
LYMPH# | 1.28(0.99~2.48)×109/L | 1.33(0.96~2.65)×109/L* | ≤15% | 97.5 | 合格 |
MONO# | 0.66(0.36~0.87)×109/L | 0.65(0.36~0.91)×109/L | 0.5×109/L | 97.5 | 合格 |
EO# | 0.11(0.03~0.23)×109/L | 0.10(0.03~0.23)×109/L | 0.2×109/L | 97.5 | 合格 |
BASO# | 0.02(0.01~0.04)×109/L | 0.02(0.01~0.04)×109/L | 0.1×109/L | 97.5 | 合格 |
[1] | 中华人民共和国卫生部. WS/T406-2012 临床血液学检验常规项目分析质量要求[S]. 北京:中华人民共和国卫生部, 2012. |
[2] | 余群秀, 沈学耕. BC6800全自动血液分析仪3种吸样模式测定结果可比性分析[J]. 中外医学研究, 2015, 13(16):70-71. |
[3] | 卢磊, 郭一星. Sysmex xs-1000i全自动血细胞分析仪两种模式检测结果比较[J]. 中国医药导报, 2010, 7(21):122-123. |
[4] | 谢萍, 李键. 不同模式检测血常规对PLT、WBC、Hb及RBC影响的对比研究[J]. 临床和实验医学杂志, 2016, 15(16):1577-1579. |
[5] | 宋政, 金竹炫. Sysmex XN1000血细胞分析仪检测模式的临床应用[J]. 大理大学学报, 2016, 1(8):67-69. |
[6] | 刘波. 不同血液分析系统准确性的评估和探讨[J]. 国际检验医学杂志, 2007, 28(2):188-189. |
[7] | 戴凤华. 末梢血预稀释与全血模式以及静脉血检测血常规的比较研究[J]. 中国医药指南, 2015, 13(25):174. |
[8] | SANDBERG S, FRASER C G, HORVATH A R, et al. Defining analytical performance specifications:Consensus Statement from the 1st Strategic Conference of the European Federation of Clinical Chemistry and Laboratory Medicine[J]. Clin Chem Lab Med, 2015, 53(6):833-835. |
[9] | Centers for Medicare and Medicaid Services, Department of Health and Human Services. Laboratory requirements:clinical laboratory improvement amendments of l988 code of federal regulations[S]. Washington DC:United States Government Printing Office, 2003. |
[1] | DENG Chenxia, MEI Yanping, ZHANG Xia, HUANG Baoshan, TIAN Dan, CAO Mengting, HU Yongqi, LIN Yongping, TIAN Lijun. Depolymerization effect of optical platelet count on reversible platelet aggregation after blood collection [J]. Laboratory Medicine, 2023, 38(11): 1087-1090. |
[2] | LU Tingyan, GU Danfeng, WANG Yahong, GE Yafang, YANG Haiou. Evaluation of vaginal secretion routine determination modes and review criteria analysis [J]. Laboratory Medicine, 2023, 38(11): 1091-1097. |
[3] | . [J]. Laboratory Medicine, 2023, 38(11): 1098-1100. |
[4] | . [J]. Laboratory Medicine, 2023, 38(10): 983-986. |
[5] | . [J]. Laboratory Medicine, 2023, 38(9): 901-904. |
[6] | . [J]. Laboratory Medicine, 2023, 38(9): 905-908. |
[7] | CHENG Xu, YANG Cunqing, PANG Bo, GU Chun, HOU Xueyun, FEI Jiaxin, WU Min, LI Jun, LIU Guijian. Number and activity of peripheral blood eosinophils in obese people [J]. Laboratory Medicine, 2023, 38(9): 855-859. |
[8] | LEI Jing, MAN Qiuhong, ZHAO Renjia, ZHANG Tiejun, JIANG Yanfeng, XU Kelin, SUO Chen, CHEN Xingdong. Elevated red blood cell distribution width increasing the risk of heart failure:a cohort study based on the UK Biobank [J]. Laboratory Medicine, 2023, 38(9): 860-864. |
[9] | DUAN Lili, JIANG Chang, ZHOU Dongmei. Role of PLR in ankylosing spondylitis patients with positive antinuclear antibody [J]. Laboratory Medicine, 2023, 38(7): 669-674. |
[10] | XIA Yanyan, XIA Yongquan, SONG Guanghao, XIA Mao. Role of coagulation-related monitoring indicators in the course of rivaroxaban anticoagulation for acute venous thromboembolism in elderly patients [J]. Laboratory Medicine, 2023, 38(5): 475-478. |
[11] | CHEN Yi, WANG Jia, XU Zhiwei, ZHAI Yaping, XUAN Weixia. Effects of different anticoagulants on phagocytosis,activation and apoptosis of in vitro neutrophil function [J]. Laboratory Medicine, 2023, 38(5): 479-483. |
[12] | YANG Liyuan, DAI Wanqin, WANG Xiaotong, LOU Xiaoli, WANG Yue, HOU Yanqiang. Effect of peripheral blood neutrophils on interferon-gamma release assay of Mycobacterium tuberculosis [J]. Laboratory Medicine, 2023, 38(5): 484-488. |
[13] | . [J]. Laboratory Medicine, 2023, 38(5): 502-504. |
[14] | . [J]. Laboratory Medicine, 2023, 38(1): 69-72. |
[15] | XIE Yuan, YI Wanwan, SHI Qiuyuan, LÜ Zhongwei, LIU Jin. Clinical value of thromboelastography and conventional coagulation tests in evaluating coagulation status of colon cancer and colon polyps [J]. Laboratory Medicine, 2022, 37(11): 1007-1011. |
Viewed | ||||||
Full text |
|
|||||
Abstract |
|
|||||